FDA Panel to Consider Pain Indication for Antidepressant

WASHINGTON (MedPage Today) — An FDA advisory committee will meet later this week to review whether the antidepressant duloxetine (Cymbalta) should be used as a treatment for chronic pain despite risks that include liver damage and skin disease.


Read more

Related posts

Leave a Reply